The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials
Abstract
OBJECTIVE: The authors conducted a review and meta-analysis of studies that compared the efficacy and tolerability of typical and second-generation antipsychotics for patients with treatment-resistant schizophrenia. METHOD: A systematic search revealed 12 controlled studies (involving 1,916 independent patients), which were included in the review. For the seven studies that compared clozapine to a typical antipsychotic, a meta-analysis was performed to examine clozapine's effects on overall psychopathology, response rate, extrapyramidal symptoms, and tardive dyskinesia. RESULTS: The meta-analysis confirmed that treatment-resistant schizophrenic patients have more favorable outcomes when treated with clozapine rather than a typical antipsychotic, as reflected by Brief Psychiatric Rating Scale total score, categorical response rate, Scale for the Assessment of Negative Symptoms score, Simpson-Angus Rating Scale score, and compliance rate. Clozapine also conferred benefits on the sickest treatment-resistant schizophrenic patients. Patients treated with olanzapine also had more favorable outcomes with regard to categorical response and compliance rates. CONCLUSIONS: In the aggregate, the results of a meta-analysis indicated that clozapine exhibits superiority over typical antipsychotics in terms of both efficacy (as measured by improvement in overall psychopathology) and safety (in terms of reduced extrapyramidal side effects). However, the magnitude of the clozapine treatment effect was not consistently robust. Efficacy data for other second-generation antipsychotics in the treatment of patients with refractory schizophrenia were inconclusive. There is, therefore, a growing need to consider new and different treatment strategies, whether they be adjunctive or monotherapeutic, for schizophrenia that continues to be resistant or only partially responsive to treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Meta-Analytic Procedures for Social Research.
Metcalfe, A., & Rosenthal, R. (1994) · The Statistician · doi:10.2307/2348600 · Cited by 4,249
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Toutenburg, H. (1974) · Biometrische Zeitschrift · doi:10.1002/bimj.19740160814 · Cited by 1,538
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,348
Keefe, R. S. E., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033374 · Cited by 693
Self-citationNovel antipsychotics: comparison of weight gain liabilities.
Wirshing, D. A., Wirshing, W. C., Kysar, L., Berisford, M. A., Goldstein, D., Pashdag, J., Mintz, J., & Marder, S. R. (1999) · PubMed · Cited by 523
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 516
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.6.856 · Cited by 486
Childhood-Onset Schizophrenia: A Double-blind Clozapine-Haloperidol Comparison
Kumra, S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830120020005 · Cited by 410
Novel Antipsychotics: Comparison of Weight Gain Liabilities
Wirshing, D. A., Wirshing, W. C., Kysar, L., Berisford, M. A., Goldstein, D., Pashdag, J., Mintz, J., & Marder, S. R. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0602 · Cited by 393
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1744 · Cited by 382
Bondolfi, G., Dufour, H., Patris, M., May, J. P., Billeter, U., Eap, C. B., & Baumann, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.4.499 · Cited by 283
Buchanan, R. W., Breier, A., Kirkpatrick, B., Ball, P., & Carpenter, W. T. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.751 · Cited by 264
Morgenstern, H. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210057007 · Cited by 260
Olanzapine Compared With Chlorpromazine in Treatment-Resistant Schizophrenia
Conley, R. R., Tamminga, C. A., Bartko, J. J., Richardson, C., Peszke, M., Lingle, J., Hegerty, J., Love, R., Gounaris, C., & Zaremba, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.914 · Cited by 245
Initial Anticholinergic Prophylaxis for Neuroleptic-Induced Extrapyramidal Syndromes
Keepers, G. A. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790090075012 · Cited by 216
Breier, A. F., Malhotra, A. K., Su, T.-P., Pinals, D. A., Elman, I., Adler, C. M., Lafargue, R. T., Clifton, A., & Pickar, D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.294 · Cited by 208
Integrating incidence and prevalence of tardive dyskinesia.
Kane, J. M., Woerner, M. G., Borenstein, M., Wegner, J. T., & Lieberman, J. A. (1986) · PubMed · Cited by 207
Self-citationPositive and negative syndromes in schizophrenia: Assessment and research.
Kay, S. R. (1991) · Medical Entomology and Zoology · Cited by 186
Risperidone in Treatment-Refractory Schizophrenia
Wirshing, D. A., Marshall, B. D., Green, M. F., Mintz, J., Marder, S. R., & Wirshing, W. C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1374 · Cited by 148
Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia
Chakos, M., Alvir, J. M., Woerner, M. G., Koreen, A., Geisler, S., Mayerhoff, D., Sobel, S., Kane, J. M., Borenstein, M., & Lieberman, J. A. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830040049009 · Cited by 140
Self-citationFrequent Rehospitalization and Noncompliance With Treatment
Green, J. H. (1988) · Psychiatric Services · doi:10.1176/ps.39.9.963 · Cited by 134
Breier, A. F., & Hamilton, S. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00291-1 · Cited by 126
Hyperglycemia Associated With Olanzapine
Fertig, M. K., Brooks, V. G., Shelton, P. S., & English, C. W. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1208c · Cited by 110
Clozapine Eligibility Among State Hospital Patients
Essock, S. M., Hargreaves, W. A., Dohm, F.-A., Goethe, J., Carver, L., & Hipshman, L. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.1.15 · Cited by 107
Neuroleptic-Induced Acute Extrapyramidal Syndromes and Tardive Dyskinesia
Casey, D. E. (1993) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30166-7 · Cited by 100
Motor and mental aspects of acute extrapyramidal syndromes
Casey, D. E. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05826.x · Cited by 68
An overview of statistical issues and methods of meta-analysis
Schmid, E. J., Koch, G. G., & LaVange, L. M. (1991) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543409108835008 · Cited by 62
Hong, C.-J., Chen, J., Chiu, H.-J., & Sim, C. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705000-00001 · Cited by 61
Service provision for people with schizophrenia
Lang, F. H., Johnstone, E. C., Murray, G. D., & Forbes, J. F. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.171.2.159 · Cited by 42
Osteoporosis associated with neuroleptic treatment. A case report.
Kartaginer, J., Ataya, K. M., Mercado, A., & Abbasi, A. A. (1990) · PubMed · Cited by 19
Atypical Antipsychotic Drugs in Treatment-Refractory Schizophrenia
Bradford, D. W., Chakos, M., Sheitman, B., & Lieberman, J. A. (1998) · Psychiatric Annals · doi:10.3928/0048-5713-19981101-06 · Cited by 12
Self-citation
Cited by
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationMillan, M. J. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00009-6 · Cited by 3,035
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Self-citationMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Self-citation
Metadata
- Authors
- Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B.
- Venue
- American Journal of Psychiatry
- Published
- 2001-04-01
- Volume
- 158
- Issue
- 4
- Pages
- 518-526
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2115115146
- Cited by
- 631
- References
- 35
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.